CJC-1295 DAC (5 mg Vial) Dosage Protocol

Plan based on an 8–16 week twice-weekly protocol with gradual titration.

• Peptide Vials (CJC-1295 DAC, 5 mg each):
  • 8 weeks: approximately 3 vials required (~10.2 mg total)
  • 12 weeks: approximately 4 vials required (~18.2 mg total)
  • 16 weeks: approximately 6 vials required (~26.2 mg total)
• Insulin Syringes (U-100):
  • Per week: 2 syringes (twice weekly)
  • 8 weeks: 16 syringes
  • 12 weeks: 24 syringes
  • 16 weeks: 32 syringes
• Bacteriostatic Water (10 mL bottles): Use ~2.0 mL per vial for reconstitution.
  • 8 weeks (3 vials): 6 mL - 1 bottle required (10 mL each)
  • 12 weeks (4 vials): 8 mL - 1 bottle required (10 mL each)
  • 16 weeks (6 vials): 12 mL - 2 bottles required (10 mL each)
• Alcohol Swabs: One for the vial stopper + one for the injection site each injection.
  • Per week: 4 swabs (2 per injection × 2 injections)
  • 8 weeks: 32 swabs - 1 box required (100 swabs each)
  • 12 weeks: 48 swabs - 1 box required (100 swabs each)
  • 16 weeks: 64 swabs - 1 box required (100 swabs each)

CJC-1295 DAC 5 mg

View Supplier

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

Practice preparing this vial with the verified strength and final volume from this protocol.

• Reconstitute: Add 2.0 mL bacteriostatic water → 2.5 mg/mL (2500 mcg/mL) concentration.
• Typical dose range: 300–1000 mcg per injection, twice weekly (gradual titration).
• Easy measuring: At 2.5 mg/mL, 1 unit = 0.01 mL = 25 mcg on a U-100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

This CJC-1295 DAC dosage protocol explains how a 5 mg vial reconstituted with 2.0 mL produces a 2.5 mg/mL concentration, then keeps the existing peptide mass, U-100 syringe units, milliliters, frequency, and vial-yield calculations together. CJC-1295 DAC is a long-acting growth hormone-releasing hormone (GHRH) analog designed to bind serum albumin. Human studies found sustained, dose-dependent increases in growth hormone and IGF-1 after subcutaneous administration, with an estimated half-life of 5.8–8.1 days^[1]. A separate human study found that GH pulsatility was preserved while mean and trough GH increased^[2]. These findings describe the investigational compound and do not validate the calculation schedule shown on this page.

This 5 mg CJC-1295 DAC vial page combines the existing calculation schedule with concentration, U-100 conversion, research context, and evidence limits needed to interpret each row.

• Goal: Support sustained GH and IGF-1 elevation for research into GH-axis effects^[1].
• Schedule: Twice-weekly subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
• Dose Range: 300–1000 mcg per injection with gradual titration.
• Reconstitution: 2.0 mL per 5 mg vial (2.5 mg/mL) for accurate unit measurements.
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Suggested twice-weekly titration approach.

• Start: 300 mcg per injection twice weekly; increase by ~250 mcg every 2 weeks as tolerated.
• Target: 750–1000 mcg per injection by Weeks 5–12.
• Frequency: Twice per week (subcutaneous), spaced 3–4 days apart.
• Cycle Length: 8–12 weeks; optional extension to 16 weeks.
• Timing: Consistent timing (e.g., evenings); rotate injection sites.

Proper storage preserves peptide quality.

• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); follow the exact product’s expiration or validated stability information; avoid freeze–thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Practical considerations for consistency and safety.

• Use new sterile insulin syringes; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document each dose, injection site, and timing to maintain consistency.
• The DAC modification provides sustained release; maintain consistent twice-weekly scheduling.
• The 5 mg vial provides more doses per vial, reducing reconstitution frequency.

CJC-1295 is a synthetic analog of growth hormone-releasing hormone. It activates the GHRH receptor on pituitary somatotrophs, which can increase pulsatile growth hormone release and downstream IGF-1 signaling^[2][4]. The Drug Affinity Complex, or DAC modification, was designed to form a reversible bond with serum albumin. Preclinical research identified CJC-1295 as a longer-lasting GRF 1-29 analog after albumin binding^[11].

In healthy adults, a single subcutaneous dose produced sustained, dose-dependent increases in mean growth hormone and IGF-1. The investigators estimated a 5.8–8.1 day half-life and observed cumulative effects after repeated administration^[1]. Those pharmacology findings explain why CJC-1295 with DAC is discussed differently from shorter-acting GHRH analogs, but they do not establish a universal CJC-1295 dose.

The principal human studies were small, controlled investigations in healthy adults. Teichman and colleagues measured pharmacokinetics and hormone responses after single or repeated subcutaneous CJC-1295 administration. Growth hormone remained elevated for at least six days and IGF-1 for nine to eleven days after a single dose, while no serious adverse reactions were reported in the study sample^[1].

A companion analysis found that CJC-1295 increased mean, trough, and integrated growth hormone concentrations without eliminating pulsatile secretion or the underlying GH pulse pattern^[2]. Later proteomic work examined serum-protein changes after activation of the GH/IGF-1 axis in normal adults and treated those changes as exploratory biomarkers rather than clinical outcomes^[12]. These studies did not validate fat-loss, muscle-growth, anti-aging, or performance claims.

CJC-1295 with DAC and peptides marketed as CJC-1295 without DAC should not be treated as interchangeable names. The DAC version is the albumin-binding compound studied as CJC-1295 in the cited human trials^[1][11]. Products described as CJC-1295 no DAC are generally associated with shorter-acting modified GRF 1-29 terminology and a different pharmacokinetic premise.

That distinction matters when reading a CJC-1295 dosage guide, comparing a CJC-1295 peptide protocol, or using a reconstitution calculator. A vial label, concentration, and syringe conversion cannot determine whether the material is the DAC or no-DAC form. Confirm the exact compound identity and lot documentation before applying any calculation.

The 5 mg vial changes concentration and vial-yield arithmetic, not the biological evidence. With 2.0 mL of bacteriostatic water, the concentration is 2.5 mg/mL, or 2,500 mcg/mL. On a U-100 syringe, one unit equals 0.01 mL and therefore represents 25 mcg at this dilution. The primary chart keeps each peptide amount beside its matching units and milliliters so a separate peptide dosage calculator is not required to interpret a row. The weekly dose column is arithmetic derived from the unchanged schedule, not a new recommendation.

The sibling 2 mg vial protocol uses its own reconstitution and unit math. Moving between vial strengths without recalculating concentration can produce an incorrect volume even when the intended peptide mass is unchanged. The supplier card documents the 5 mg product source used for this page^[10].

Human CJC-1295 research supports a biochemical finding: the compound can increase growth hormone and IGF-1 for several days after subcutaneous administration^[1][2]. It does not establish a treatment benefit, a body-composition result, or a recommended CJC-1295 dosage for the public. General physiology sources explain how the GH/IGF-1 axis relates to growth and metabolism, but that background should not be presented as proof that CJC-1295 improves fat loss or muscle growth^[4][9].

The published trials were small and short. Reported events included injection-site reactions, flushing, headache, transient hypotension, diarrhea, and dose-related tolerability findings; the available safety data are not sufficient to characterize long-term risk^[1]. CJC-1295 is investigational and is not FDA-approved. Product identity, purity, sterility, and lot documentation are separate uncertainties outside the clinical studies.

Growth hormone secretion varies with age, sex, sleep, nutrition, body composition, exercise, illness, and time of day^[4]. Those variables complicate comparisons between studies, online anecdotes, and a single laboratory result. Animal research also cannot substitute for human outcomes; the mouse growth model supplies mechanistic context only^[13]. A claim about recovery, body weight, fat loss, or body composition should be separated from the hormone measurements actually reported in CJC-1295 trials.

Also separate CJC-1295 with DAC from no-DAC formulations and from CJC-1295 and ipamorelin stacks. Ipamorelin is a different growth hormone secretagogue with a different receptor target; combining names in search results does not make their evidence or dosing protocols interchangeable. This page addresses the 5 mg CJC-1295 DAC vial only.

General subcutaneous guidance from clinical best-practice resources^[5][6].

• Clean the vial stopper and skin with alcohol; allow to dry.
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue^[5][8].
• Do not aspirate for subcutaneous injections; inject slowly and steadily^[5].
• Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy^[6][7].
• Do not rub or massage the injection site after administration^[8].

How is the 5 mg vial calculated after adding 2 mL?

Five milligrams divided by 2.0 mL equals 2.5 mg/mL, or 2,500 mcg/mL. This is a concentration calculation, not a recommendation.

How much CJC-1295 DAC is in one U-100 syringe unit?

At 2.5 mg/mL, one U-100 unit equals 0.01 mL and contains 25 mcg. Always recalculate if the final volume changes.

Is CJC-1295 with DAC the same as CJC-1295 no DAC?

No. The DAC version uses an albumin-binding modification associated with a longer half-life. Products described as no DAC follow a different pharmacokinetic premise and should not share calculations without verifying the exact compound.

What did the human CJC-1295 studies measure?

The main studies measured pharmacokinetics, growth hormone, IGF-1, pulsatility, and short-term tolerability in healthy adults^[1][2]. They did not establish a public treatment protocol or prove body-composition outcomes.

Why does vial strength matter if the peptide is the same?

Vial strength affects concentration, syringe volume, and vial yield after reconstitution. It does not by itself change the compound’s pharmacology or create a new evidence-based dose.

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

• 1
  
  J Clin Endocrinol Metab (2006)
  - Teichman SL et al. Prolonged stimulation of GH and IGF-1 by CJC-1295 in healthy adults

  View Source
• 2
  
  J Clin Endocrinol Metab (2006)
  - Ionescu M et al. Pulsatile GH secretion persists during continuous CJC-1295 stimulation

  View Source
• 4
  
  StatPearls (NCBI Bookshelf)
  - Brinkman JE et al. Physiology, Growth Hormone

  View Source
• 5
  
  CDC Pink Book (Chapter 6)
  - Vaccine administration: subcutaneous route (angle/site; no aspiration)

  View Source
• 6
  
  Johns Hopkins Arthritis Center
  - How to give a subcutaneous injection (patient guidance)

  View Source
• 7
  
  StatPearls (NCBI Bookshelf)
  - Regular Insulin: subcutaneous administration and site rotation

  View Source
• 8
  
  Immunize Canada
  - How to Vaccinate: Best Practices (subcutaneous injection technique)

  View Source
• 9
  
  Postgrad Med J (2006)
  - Ayuk J, Sheppard MC. Growth hormone and its disorders

  View Source
• 10
  
  Pure Lab Peptides
  - CJC-1295 DAC (5 mg) product page (quality and batch documentation)

  View Source
• 11
  Endocrinology (2005) - Jetté L et al. Identification of CJC-1295 as a long-lasting GRF analog after albumin bioconjugation

  View Source
• 12
  Growth Horm IGF Res (2009) - Sackmann-Sala L et al. Serum-protein changes after GH/IGF-1 axis activation by CJC-1295 in normal adults

  View Source
• 13
  Am J Physiol Endocrinol Metab (2006) - Alba M et al. Once-daily CJC-1295 in a GHRH-knockout mouse model

  View Source

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-strength variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.